< Essential uses: Laboratory and analytical uses Up one level Decision VIII/10: Actions by Parties to promote industry's participation on a smooth and efficient transition away from CFC-based MDIs > Essential uses: Metered-dose inhalers (MDIs) Decision VIII/10: Actions by Parties to promote industry's participation on a smooth and efficient transition away from CFC-based MDIs Decision VIII/11: Measures to facilitate a transition by a Party from CFC-based MDIs Decision VIII/12: Information gathering on a transition to non-CFC treatments for asthma and chronic obstructive pulmonary disease for Parties not operating under Article 5 Decision IX/19: Metered-dose inhalers (MDIs) Decision IX/20: Transfer of essential-use authorizations for CFCs for MDIs Decision XII/2: Measures to facilitate the transition to chlorofluorocarbon-free metered-dose inhalers Decision XIII/9: Metered-dose inhaler (MDI) production Decision XIII/10: Further study of campaign production of CFCs for metered-dose inhalers (MDIs) Decision XIV/4: Essential-use nominations for non-Article 5 Parties for controlled substances for 2003 and 2004 Decision XIV/5: Global database and assessment to determine appropriate measures to complete the transition from chlorofluorocarbon metered-dose inhalers Decision XV/4: Essential use nominations for non-Article 5 Parties for controlled substances for 2004 and 2005 Decision XV/5: Promoting the closure of essential-use nominations for metered-dose inhalers Decision XVI/12: Essential-use nominations for Parties not operating under paragraph 1 of Article 5 of the Montreal Protocol for controlled substances for 2005 and 2006 Decision XVII/5: Essential-use nominations for Parties for controlled substances for 2006 and 2007 Decision XVII/14: Difficulties faced by some Parties operating under paragraph 1 of Article 5 of the Montreal Protocol with respect to chlorofluorocarbons used in the manufacture of metered-dose inhalers Decision XVIII/7: Essential-use exemptions for Parties for controlled substances for 2007 and 2008 Decision XVIII/16: Difficulties faced by some Article 5 Parties manufacturing metered-dose inhalers which use chlorofluorocarbons Decision XIX/13: Essential-use nominations for Parties for controlled substances for 2008 and 2009 Decision XX/2: Essential-use nominations for Parties not operating under paragraph 1 of Article 5 for controlled substances for 2009 and 2010 Decision XX/3: Essential-use exemptions for Parties operating under paragraph 1 of Article 5 Decision XX/4: Campaign production of chlorofluorocarbons for metered-dose inhalers Decision XXI/4: Essential-use nominations for controlled substances for 2010 Decision XXII/4: Essential-use nominations for controlled substances for 2011 Decision XXIII/2: Essential-use nominations for controlled substances for 2012 Decision XXIV/3: Essential-use nominations for controlled substances for 2013 Decision XXV/2: Essential-use nominations for controlled substances for 2014 Decision XXVI/2: Essential-use nominations for controlled substances for 2015 Decision XXXVI/6: Developments regarding metered-dose inhalers with low-global-warming-potential propellants < Essential uses: Laboratory and analytical uses Up one level Decision VIII/10: Actions by Parties to promote industry's participation on a smooth and efficient transition away from CFC-based MDIs >
